Vdac inhibitors for treating autoimmune diseases
AssigneesThe National Institute for Biotechnology In the Negev Ltd., The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsVarda SHOSHAN-BARMATZ, Jay CHANG, Jeonghan KIM
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for treating diseases associated with type-1 interferon signaling. Particularly, the present invention is directed to use of specific inhibitors of Voltage-Dependent Anion Channel (VDAC1), such as piperazine- and/or piperidine-derivatives, among others, e.g., peptides and oligonucleotides, for treating an autoimmune disease.
Claims33
A method for slowing the progression of or treating an autoimmune disease comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of a VDAC inhibiting compound.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.